Sandra A Springer1,2, Angela Di Paola3, Russell Barbour2, Marwan M Azar1, Frederick L Altice1,2,4,5. 1. Department of Internal Medicine, Section of Infectious Diseases, AIDS Program, Yale School of Medicine, New Haven, CT. 2. Center for Interdisciplinary Research on AIDS, Yale University School of Public Health, New Haven, CT. 3. School of Public Health, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX. 4. Division of Epidemiology of Microbial Diseases, Yale University School of Public Health, New Haven, CT. 5. Centre of Excellence in Research in AIDS (CERiA), University of Malaya, Kuala Lumpur, Malaysia.
Abstract
OBJECTIVE: To determine whether extended-release naltrexone (XR-NTX) would improve or maintain viral suppression (VS) among incarcerated individuals with HIV and alcohol use disorders (AUDs) transitioning to the community. DESIGN: A randomized, double-blind, placebo-controlled trial was conducted among incarcerated individuals with HIV and AUDs transitioning to the community from 2010 through 2016. METHODS:Eligible participants (N = 100) were randomized 2:1 to receive 6 monthly injections of XR-NTX (n = 67) or placebo (n = 33) starting at release and continued for 6 months. The primary and secondary outcomes were the proportion that maintained or improved VS at <200 and <50 copies per milliliter from baseline to 6 months, respectively, using an intention-to-treat analysis. RESULTS: Participants allocated to XR-NTX improved VS from baseline to 6 months for <200 copies per milliliter (48.0%-64.2%, P = 0.024) and for <50 copies per milliliter (31.0%-56.7%, P = 0.001), whereas the placebo group did not (<200 copies/mL: 64%-42.4%, P = 0.070; <50 copies/mL: 42.0%-30.3%, P = 0.292). XR-NTX participants were more likely to achieve VS than the placebo group at 6 months (<200 copies/mL: 64.2% vs. 42.4%; P = 0.041; <50 copies/mL: 56.7% vs. 30.3%; P = 0.015). XR-NTX independently predicted VS [<200 copies/mL: adjusted odds ratio (aOR) = 2.68, 95% confidence interval (CI) = 1.01 to 7.09, P = 0.047; <50 copies/mL: aOR = 4.54; 95% CI = 1.43 to 14.43, P = 0.009] as did receipt of ≥3 injections (<200 copies/mL: aOR = 3.26; 95% CI = 1.26 to 8.47, P = 0.010; <50 copies/mL: aOR = 6.34; 95% CI = 2.08 to 19.29, P = 0.001). Reductions in alcohol consumption (aOR = 1.43, 95% CI = 1.03 to 1.98, P = 0.033) and white race (aOR = 5.37, 95% CI = 1.08 to 27.72, P = 0.040) also predicted VS at <50 copies per milliliter. CONCLUSIONS:XR-NTX improves or maintains VS after release to the community for incarcerated people living with HIV and AUDs.
RCT Entities:
OBJECTIVE: To determine whether extended-release naltrexone (XR-NTX) would improve or maintain viral suppression (VS) among incarcerated individuals with HIV and alcohol use disorders (AUDs) transitioning to the community. DESIGN: A randomized, double-blind, placebo-controlled trial was conducted among incarcerated individuals with HIV and AUDs transitioning to the community from 2010 through 2016. METHODS: Eligible participants (N = 100) were randomized 2:1 to receive 6 monthly injections of XR-NTX (n = 67) or placebo (n = 33) starting at release and continued for 6 months. The primary and secondary outcomes were the proportion that maintained or improved VS at <200 and <50 copies per milliliter from baseline to 6 months, respectively, using an intention-to-treat analysis. RESULTS:Participants allocated to XR-NTX improved VS from baseline to 6 months for <200 copies per milliliter (48.0%-64.2%, P = 0.024) and for <50 copies per milliliter (31.0%-56.7%, P = 0.001), whereas the placebo group did not (<200 copies/mL: 64%-42.4%, P = 0.070; <50 copies/mL: 42.0%-30.3%, P = 0.292). XR-NTXparticipants were more likely to achieve VS than the placebo group at 6 months (<200 copies/mL: 64.2% vs. 42.4%; P = 0.041; <50 copies/mL: 56.7% vs. 30.3%; P = 0.015). XR-NTX independently predicted VS [<200 copies/mL: adjusted odds ratio (aOR) = 2.68, 95% confidence interval (CI) = 1.01 to 7.09, P = 0.047; <50 copies/mL: aOR = 4.54; 95% CI = 1.43 to 14.43, P = 0.009] as did receipt of ≥3 injections (<200 copies/mL: aOR = 3.26; 95% CI = 1.26 to 8.47, P = 0.010; <50 copies/mL: aOR = 6.34; 95% CI = 2.08 to 19.29, P = 0.001). Reductions in alcohol consumption (aOR = 1.43, 95% CI = 1.03 to 1.98, P = 0.033) and white race (aOR = 5.37, 95% CI = 1.08 to 27.72, P = 0.040) also predicted VS at <50 copies per milliliter. CONCLUSIONS:XR-NTX improves or maintains VS after release to the community for incarcerated people living with HIV and AUDs.
Authors: Jaimie P Meyer; Javier Cepeda; Johnny Wu; Robert L Trestman; Frederick L Altice; Sandra A Springer Journal: JAMA Intern Med Date: 2014-05 Impact factor: 21.873
Authors: Anne Zinski; Andrew O Westfall; Lytt I Gardner; Thomas P Giordano; Tracey E Wilson; Mari-Lynn Drainoni; Jeanne C Keruly; Allan E Rodriguez; Faye Malitz; D Scott Batey; Michael J Mugavero Journal: Am J Public Health Date: 2015-08-13 Impact factor: 9.308
Authors: Panagiotis Vagenas; Angela Di Paola; Maua Herme; Thomas Lincoln; Daniel J Skiest; Frederick L Altice; Sandra A Springer Journal: J Subst Abuse Treat Date: 2014-03-12
Authors: Jaimie P Meyer; Javier Cepeda; Sandra A Springer; Johnny Wu; Robert L Trestman; Frederick L Altice Journal: Lancet HIV Date: 2014-11-01 Impact factor: 12.767
Authors: Frederick L Altice; Duncan Smith-Rohrberg Maru; R Douglas Bruce; Sandra A Springer; Gerald H Friedland Journal: Clin Infect Dis Date: 2007-08-13 Impact factor: 9.079
Authors: Matthew S Stein; Anne C Spaulding; Marc Cunningham; Lauren C Messina; Bryan I Kim; Koo-Whang Chung; Jeffrey Draine; Alison O Jordan; Adrena Harrison; Ann K Avery; Timothy P Flanigan Journal: AIDS Behav Date: 2013-10
Authors: Elizabeth L C Merrall; Azar Kariminia; Ingrid A Binswanger; Michael S Hobbs; Michael Farrell; John Marsden; Sharon J Hutchinson; Sheila M Bird Journal: Addiction Date: 2010-06-23 Impact factor: 6.526
Authors: Benjamin J Oldfield; Kathleen A McGinnis; E Jennifer Edelman; Emily C Williams; Adam J Gordon; Kathleen Akgün; Stephen Crystal; Lynn E Fiellin; Julie R Gaither; Joseph L Goulet; P Todd Korthuis; Brandon D L Marshall; Amy C Justice; Kendall Bryant; David A Fiellin; Kevin L Kraemer Journal: J Subst Abuse Treat Date: 2019-11-06
Authors: Divya K Chandra; Alexander R Bazazi; Muzammil A Nahaboo Solim; Adeeba Kamarulzaman; Frederick L Altice; Gabriel J Culbert Journal: HIV Res Clin Pract Date: 2019-05-01
Authors: Robert L Cook; Zhi Zhou; Maria Jose Miguez; Clery Quiros; Luis Espinoza; John E Lewis; Babette Brumback; Kendall Bryant Journal: Alcohol Clin Exp Res Date: 2019-07-10 Impact factor: 3.455